Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Metrics to compare | DB0 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDB0PeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −3.0x | −0.5x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price/Book | −1.8x | 2.6x | 2.6x | |
Price / LTM Sales | - | 54.7x | 3.3x | |
Upside (Analyst Target) | - | 194.1% | 42.9% | |
Fair Value Upside | Unlock | 5.3% | 6.2% | Unlock |